Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients

被引：19
|
作者：
Kawai, Taketo [1 ]
Sato, Yusuke [1 ]
Makino, Katsuhiro [1 ]
Yamada, Yuta [1 ]
Nomiya, Akira [1 ]
Nakamura, Masaki [1 ]
Yamada, Daisuke [1 ]
Suzuki, Motofumi [1 ]
Igawa, Yasuhiko [1 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷
关键词：
ASSOCIATION; NIVOLUMAB;
D O I：
10.1016/j.ejca.2019.05.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [31] Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database
    Tan, Feilong
    Zhou, Li
    Huang, Guijiang
    Li, Yanhua
    Yin, Wenjie
    Xia, Hongying
    ONCOLOGY, 2025,
  • [32] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Immanuel Augustin Oppolzer
    Josef Riester
    Roland Büttner
    Maximilian Burger
    Marco Julius Schnabel
    International Urology and Nephrology, 2023, 55 : 1943 - 1949
  • [33] Nivolumab in melanoma: immune-related adverse events and efficacy
    Reactions Weekly, 2019, 1735 (1) : 11 - 11
  • [34] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Oppolzer, Immanuel Augustin
    Riester, Josef
    Buettner, Roland
    Burger, Maximilian
    Schnabel, Marco Julius
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (08) : 1943 - 1949
  • [35] Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials
    Naleid, Nikolas
    Mears, Veronica
    Kakish, Hanna
    Mahipal, Amit
    Chakrabarti, Sakti
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 744 - 744
  • [36] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sandigursky, Sabina
    Mor, Adam
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
  • [37] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sabina Sandigursky
    Adam Mor
    Current Rheumatology Reports, 2018, 20
  • [38] Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer
    Samanci, Nilay Sengul
    Cikman, Duygu Ilke
    Oruc, Kerem
    Bedir, Sahin
    Celik, Emir
    Degerli, Ezgi
    Derin, Sumeyra
    Demirelli, Fuat Hulusi
    Ozguroglu, Mustafa
    TUMORI JOURNAL, 2021, 107 (04): : 304 - 310
  • [39] Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab
    Castel-Ajgal, Zahra
    Goulvestre, Claire
    Zaibet, Sonia
    Arrondeau, Jennifer
    Bretagne, Marie
    Peyromaure, Michael
    Batteux, Frederic
    Alexandre, Jerome
    Goldwasser, Francois
    Huillard, Olivier
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : E362 - E368
  • [40] Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
    Rogado, J.
    Pacheco Barcia, V.
    Vera, B.
    Toquero, P.
    Mondejar, R.
    Ballesteros Garcia, A. I.
    Donnay, O.
    Romero Laorden, N.
    Colomer Bosch, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S112 - S112
12345